* Among the human studies, 9 evaluated testosterone levels (total and/or free), 6 reported on gonadotropins (LH, FSH), and 5 assessed clinical hypogonadal symptoms such as libido and erectile function. In total, 7 human studies demonstrated a statistically significant increase in testosterone levels following GLP-1 agonist treatment, with stronger effects observed in men with obesity, T2DM, and baseline low testosterone. Two human studies showed no change or mild reductions in testosterone among eugonadal men without metabolic disease.
* Given emerging data on sarcopenia and GLP-1 RAs, future studies should investigate the potential role of combined GLP-1 and testosterone therapies to optimize outcomes in body composition, metabolic control, and sexual health.
Table 1. Impact of GLP-1 Receptor Agonist Therapy on Testosterone Levels, Sexual Healthm and Metabolic parameters in Men with Obesity or Type 2 Diabetes: Summary statistics
PRELIMINARY ASSESSMENT OF GLP-1 RECEPTOR AGONISTSON TESTOSTERONE LEVELS, ERECTILE FUNCTION, ANDMETABOLIC OUTCOMES IN MEN WITH OBESITY OR TYPE...
ExcelMale Newsletter Signup
Stay Informed with Our Newsletter
Get the latest men's health insights, expert advice, and community updates delivered to your inbox.